HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CIR Director Gill Steps Down, Leaving Legacy Of Improved Transparency

This article was originally published in The Rose Sheet

Executive Summary

Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.

You may also be interested in...

CIR Slated To Examine New Paraben Data At Next Meeting

The Cosmetic Ingredient Review Expert Panel will take another look at paraben safety during its June meeting, considering new studies and adding ingredients to its assessment on the preservative group. NGO Women’s Voices for the Earth suggests that the panel may still be missing several relevant studies.

WVE Letter Prompts CIR Panel To Rethink Aerosol Cosmetics, Inhalation

Going into the Cosmetic Ingredient Review Expert Panel’s review of boilerplate language for aerosols, Women’s Voices for the Earth raised concerns about aerosol particle sizes and the potential for respiratory harm from inhalation. Panel members agreed that the NGO presented some valid points and said they plan to look into updates.

PCPC Hatching Proposal For CIR Role In FDA Ingredient Review

The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts